未识别的纤维蛋白原A α链淀粉样变性:靶向基因检测结果
在葡萄牙布拉加地区对透析人群及家系成员进行FGA p.Glu545Val变异靶向基因检测,发现该变异在透析患者中占9.8%、在受检亲属中占49%,共50例来自13个无亲缘关系家系,提示该病在当地被低估。
要点
- FGA p.Glu545Val变异在布拉加透析患者中检出率为9.8%,在受检亲属中为49%。
- 50例变异携带者来自13个无亲缘关系家系,61%的先证者存在肾脏病或淀粉样变性。
- 25%的AFib淀粉样变性透析患者既往肾脏病被归因于高血压。
核心结论
- AFib淀粉样变性在葡萄牙布拉加可能被低估,该地区FGA p.Glu545Val变异频率高。
- 由于主要临床特征非特异,诊断AFib淀粉样变性应保持高度怀疑,尤其在高血压普遍的人群中。
研究设计与样本
- 病例系列研究。
- 研究纳入3组参与者:肾活检登记组n=4;血液透析机构267例患者中的122例;基因高风险家庭成员167人中的69人。
主要发现
- p.Glu545Val变异在肾活检登记组4例中全部检出,在122例受检透析患者中检出12例(9.8%),在69例受检亲属中检出34例(49%)。
- 上述50例来自13个无亲缘关系家系,61%的先证者存在肾脏病或淀粉样变性。
- 35例在平均51.0±10.4岁时表现为高血压;其中30例在平均56.7±12.0岁时发生肾脏病,21例在平均61.4±11.3岁时开始透析。
- 疾病进展过程中心脏、肝脏、脾脏、结肠和回肠受累。
- 25%的接受血液透析的AFib淀粉样变性患者,其肾脏病既往被归因于高血压。
局限性
- 对既往已诊断淀粉样变性患者的数据收集为回顾性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibrinogen A α-chain (AFib) amyloidosis results from autosomal-dominant mutations in the gene encoding AFib (FGA). Patients with this disorder typically present with proteinuria. Isolated cases of AFib amyloidosis, carrying the FGA p.Glu545Val variant, were identified in the district of Braga, in northwest Portugal. This observation led us to hypothesize that this disorder might be an unrecognized cause of kidney disease in that region and prompted us to carry out targeted genetic testing for the p.Glu545Val variant in the local hemodialysis population and family members of identified cases. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: 3 groups of participants: (1) kidney biopsy registry, n=4; (2) hemodialysis facility, n=122 of 267 patients; and (3) genetically at-risk individuals; n=69 of 167 family members. OUTCOMES: Kidney disease, kidney disease progression, and survival. RESULTS: The p.Glu545Val variant was identified in all 4 patients of the biopsy registry, 12 of 122 (9.8%) hemodialysis patients tested, and 34 of 69 (49%) relatives tested. These 50 cases belonged to 13 unrelated families with kidney disease or amyloidosis identified in 61% of probands. 35 individuals presented with hypertension at a mean of 51.0±10.4 years. Of these, 30 developed kidney disease at a mean of 56.7±12.0 years, and 21 initiated dialysis therapy at a mean of 61.4±11.3 years. Heart, liver, spleen, colon, and ileum were involved along the progression of the disease. Kidney disease was formerly attributed to hypertension in 25% of patients with AFib amyloidosis undergoing hemodialysis. LIMITATIONS: Retrospective data collection for patients with amyloidosis previously diagnosed. CONCLUSIONS: AFib amyloidosis appears to be an under-recognized disorder in Braga, Portugal, where we found a high frequency of the FGA p.Glu545Val variant. Due to the nonspecific nature of its major clinical features, the diagnosis of AFib amyloidosis should have a high index of suspicion, particularly in populations in which hypertension is prevalent.
引用
- Tavares I, Oliveira JP, Pinho A, et al. Unrecognized Fibrinogen A α-Chain Amyloidosis: Results From Targeted Genetic Testing. Am J Kidney Dis. 2017. PMID: 28359658. doi:10.1053/j.ajkd.2017.01.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。